COMP <GO>
AUPH vs HRMY // RETURN ON INVESTED CAPITAL (ROIC)
Aurinia Pharmaceuticals Inc (NASDAQ) VS. Harmony Biosciences Holdings Inc. (NASDAQ) • 15-METRIC TALLY: AUPH 7
— HRMY 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: HRMY
LAST: $17.21 (-0.86%) • MKT CAP: $2.29B
roic
16.50%
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
roic
63.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. HRMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | HRMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 77.20% | +11.30 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 16.50% | 63.00% | -46.50 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | 7.8x | +13.30 | HRMY | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 15.48% | -9.56 | HRMY | /fcf-yield <GO> |
| Operating Margin | 37.10% | 24.00% | +13.10 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 18.30% | +49.70 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | 21.50% | -1.10 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.33 | 5.38 | +2.95 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 50.0 | +7.30 | AUPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | 11.9x | -5.20 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $2.25B | $42.5M | AUPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | HRMY REV | AUPH GROSS % | HRMY GROSS % | AUPH FCF | HRMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $868.5M | 88.5% | 77.2% | $135.7M | $347.9M |
| FY 2024 | $235.1M | $714.7M | 88.0% | 78.1% | $44.4M | $218.7M |
| FY 2023 | $175.5M | $582.0M | — | — | -$33.5M | $219.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
HRMY // BETA —